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ABSTRACT
Purpose: The University of Surrey-Lilly Real World
Evidence (RWE) diabetes cohort has been established
to provide insights into the management of type 2
diabetes mellitus (T2DM). There are 3 areas of study
due to be conducted to provide insights into T2DM
management: exploration of medication adherence,
thresholds for changing diabetes therapies, and
ethnicity-related or socioeconomic-related disparities in
management. This paper describes the identification of
a cohort of people with T2DM which will be used for
these analyses, through a case finding algorithm, and
describes the characteristics of the identified cohort.
Participants: A cohort of people with T2DM was
identified from the Royal College of General
Practitioners Research and Surveillance Centre (RCGP
RSC) data set. This data set comprises electronic
patient records collected from a nationally distributed
sample of 130 primary care practices across England
with scope to increase the number of practices to 200.
Findings to date: A cohort (N=58 717) of adults with
T2DM was identified from the RCGP RSC population
(N=1 260 761), a crude prevalence of diabetes of 5.8%
in the adult population. High data quality within the
practice network and an ontological approach to
classification resulted in a high level of data
completeness in the T2DM cohort; ethnicity
identification (82.1%), smoking status (99.3%),
alcohol use (93.3%), glycated haemoglobin (HbA1c;
97.9%), body mass index (98.0%), blood pressure
(99.4%), cholesterol (87.4%) and renal function
(97.8%). Data completeness compares favourably to
other, similarly large, observational cohorts. The cohort
comprises a distribution of ages, socioeconomic and
ethnic backgrounds, diabetes complications, and
comorbidities, enabling the planned analyses.
Future plans: Regular data uploads from the RCGP
RSC practice network will enable this cohort to be
followed prospectively. We will investigate medication
adherence, explore thresholds and triggers for
changing diabetes therapies, and investigate any
ethnicity-related or socioeconomic-related disparities in
diabetes management.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a
growing problem worldwide and is associated
with an increased risk of cardiovascular disease
and mortality.1–4 Many glucose-lowering agents
have become available in recent years in-
cluding three new classes of medication:
dipeptidase IV (DPP4) inhibitors, glucagon-
like peptide 1 (GLP1) receptor agonists and
sodium glucose co-transporter 2 inhibitors.
With the addition of these newer therapies,
the management of T2DM has become more
complex.5–7 With this increasingly complex
array of therapies, it is more important than
ever to scrutinise the relative clinical effect-
iveness of different drug classes in the real-
world setting.8 9 Selecting optimal second
and third line glucose-lowering therapies has
become difﬁcult for clinicians as there is
limited evidence to support the use of one
therapy over another in clinical practice.10 11
While the newer agents have demonstrated
Strengths and limitations of this study
▪ A large cohort of people with type 2 diabetes
was defined that has a higher level of data com-
pleteness than other similar observational
cohorts.
▪ The cohort comprises a distribution of ages,
socioeconomic and ethnic backgrounds, diabetes
complications, and comorbidities.
▪ The network of primary care practices from
which data were included comprise volunteer
practices which may not be fully representative
of the national management and outcomes in
people with type 2 diabetes.
▪ Data analysis using this cohort will be observa-
tional and therefore limited by the nature of
observational studies.
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blood glucose-lowering efﬁcacy in clinical trials and
good cardiovascular safety proﬁles (and even potential
cardiovascular beneﬁt with empagliﬂozin and liraglu-
tide),12–17 their effectiveness in the real-world setting
should be monitored, particularly as patient proﬁles
often differ from those included in trials.11
We have identiﬁed a large, real-world cohort of people
with T2DM which we will use to investigate three impor-
tant components of diabetes management in clinical
practice: (1) medication adherence and persistence, (2)
thresholds for changing therapies (in particular treatment
intensiﬁcation), and (3) socioeconomic and ethnic dis-
parities in management:
1. Adherence and persistence are thought to differ
markedly between the clinical trial setting and routine
clinical practice. Adherence also declines with increas-
ing complexity of treatment.18 19 Reduced medication
adherence is associated with poorer glycaemic
control,20–23 increased hospital admissions24–27 and
increased mortality.26 28 Using the cohort described
here, we aim to quantify the level of medication adher-
ence to newer and older therapies in the real-world
setting.
2. Glucose control in clinical practice is frequently sub-
optimal.29 A key factor contributing to this is delay in
treatment intensiﬁcation of glucose-lowering therapy
in real-world practice (termed clinical inertia).
Despite clinical inertia being identiﬁed nearly
10 years ago,30 31 the most recent studies do not show
any move towards earlier intensiﬁcation of treat-
ment.32 This may be partially due to patients’ and
providers’ reluctance to initiate injectable therapies,33
and partially due to concerns that glycaemic targets
are not always achieved even with addition of
insulin.34 35 We also intend to use this cohort to
further explore factors which predict treatment
intensiﬁcation and to attempt to identify modiﬁable
clinical factors which may delay or prevent good gly-
caemic control through treatment intensiﬁcation. In
the UK, the Quality and Outcomes Framework
(QOF), an annual reward and incentive programme
for general practitioners, sets targets for the manage-
ment of diabetes (and multiple other conditions and
aspects of care).36 We will also identify the impact of
the changing QOF glycaemic control targets on treat-
ment intensiﬁcation.
3. In our preliminary analyses, we have identiﬁed some
disparities in medication prescriptions37 and medica-
tion adherence across socioeconomic and ethnic
groups. We intend to use this cohort to explore these
potential disparities further.
The cohort described here has been identiﬁed using
routinely collected data from primary care centres in
England. Electronic health records in the UK are coded
using Read codes. This system enables coding of infor-
mation including patient demographics, medical condi-
tions, test results, processes of care and other important
healthcare-related data. However, these data have some
limitations, and in diabetes in particular, people are
often misclassiﬁed or miscoded.38 39 QOF targets in
primary care, based on clinical codes, have improved
clinical coding but difﬁculties in correct identiﬁcation of
people with diabetes remain. We describe the methods
used to minimise the impact of coding limitations and
to identify a cohort of people with T2DM. We also
describe the characteristics of this T2DM population.
COHORT DESCRIPTION
The cohort comprises all adults with T2DM identiﬁed
from practices participating in the Royal College of
General Practitioners Research and Surveillance Centre
(RCGP RSC) network. This data set consists of data col-
lected from 130 primary care practices across England,
with ongoing recruitment of practices. The RCGP RSC
network comprises 1.7% of all primary care practices in
England (N=7779).40 Only people who were alive and
registered with their current practice on 31 July 2015
have been included for analysis. People who were under
18 years old on this date were excluded from the cohort.
We use a two-step informatics ontology-based process
to identify people with T2DM. Initially all people with
diabetes were identiﬁed using a combination of clinical
codes (see below). People were then subcategorised into
diabetes type 1, type 2 or other, using a seven-step algo-
rithm. We have used all available electronic patient
records prior to 31 July 2015 to identify the cohort.
Ongoing data uploads from the participating practices
will provide prospective follow-up data.
Method for identification and classification of the cohort
Step 1: identification of people with diabetes
People with diabetes were identiﬁed using a combin-
ation of diagnostic codes, investigation results and medi-
cation codes. We have used all commonly recorded,
major diagnostic codes, as well as process of care codes
for the diagnosis of diabetes (see online supplementary
table S1) and excluded codes speciﬁc to gestational
diabetes, steroid-induced diabetes or other forms of
secondary diabetes.
Investigation results included both blood glucose and
glycated haemoglobin (HbA1c) measurements. Glucose
‘Read codes’ were stratiﬁed by test provenance (fasting,
random, glucose tolerance test, unknown or other)
using a categorisation system that we have previously
described.41 Individuals were included if they had two or
more recorded glucose values which met the diagnostic
criteria for diabetes (≥7.0 mmol/L for fasted samples
and ≥11.1 mmol/L for random samples; samples taken
at 2 hours, postglucose load, as part of a glucose toler-
ance test, or where the provenance of the test was
unknown).42 Individuals were also included if they had
two or more measurements of HbA1c above the diagnos-
tic threshold; ≥48 mmol/mol (6.5%).43 Individuals with
a single laboratory measurement consistent with diabetes
were not included unless they met one of the other
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criteria for diabetes. Finally, people were also included
in the diabetes cohort if they had been prescribed oral
hypoglycaemic agents (except metformin) or if they had
been prescribed insulin (on at least two occasions) or
GLP1 analogues.
Step 2: classification of diabetes
Once identiﬁed as having diabetes, we categorised
people as either type 1 diabetes mellitus (T1DM) or
T2DM using the algorithm shown in ﬁgure 1. Given the
occasional inaccuracy in clinical recording of diabetes
type, the ﬁrst three steps of this categorisation algorithm
allows over-riding of diagnostic codes where clinical
characteristics are highly likely to indicate a speciﬁc type
of diabetes:
Step 1: If the person had insulin initiated before age
35 and no oral agent use ever recorded (except metfor-
min), they are categorised as having T1DM.
Step 2: If on multiple oral hypoglycaemic agents, the
person is categorised as T2DM.
Step 3: If on one or more oral hypoglycaemic agent,
excluding metformin, for more than 12 months and no
history of insulin use, the person is categorised as T2DM.
If none of these criteria are met, then step 4 searches
for diagnostic codes with no evidence of conﬂict; if all
clinically entered codes are consistent with either T1DM
or T2DM, then the person is categorised accordingly.
Occasionally, people are coded as having both T1DM
and T2DM and so would be considered to have a con-
ﬂicting code type. If there are no recorded diagnostic
codes or codes are conﬂicting, then the algorithm pro-
ceeds through steps 5–7:
Step 5: If there is no documented insulin use in the
entire clinical record, then the person is categorised as
T2DM.
Step 6: If prescribed oral hypoglycaemic agents for more
than 12 months, then the person is categorised as T2DM.
Step 7: If the body mass index (BMI) measured nearest
to the time of diagnosis is ≥25 kg/m2, then the person
is categorised as T2DM.
Figure 1 Seven-step algorithm for categorising type of diabetes. 1Excluding prescriptions for metformin. BMI, body mass index;
OHA, oral hypoglycaemic agent.
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If the type of diabetes is not identiﬁed by these steps,
then the type is categorised as ‘undetermined’. People
with an undetermined diabetes type will not be included
in any subsequent analyses. We report the absolute rate
of diabetes in the population and age–gender direct
standardised rate, adjusted using the 2011 UK census.44
Method for describing the cohort
We describe the demographic, social and clinical
characteristics of the identiﬁed cohort. The demograph-
ics of people included in the cohort are reported using
descriptive statistics; age (as of 31 July 2015), gender and
ethnicity. Ethnicity recording in primary care is limited
with between 44.5% and 75.4% ethnicity recording in
diabetes populations.45 Ethnicity identiﬁcation was
therefore extended using an informatics ontology which
uses a combination of ethnicity codes and codes which
infer ethnicity (such as area-speciﬁc languages).46 All
inferential codes were checked for consistency with
deﬁnitive ethnicity codes (>0.85 positive predictive value
for ethnic group). We are due to report this ethnicity
identiﬁcation algorithm elsewhere (results under peer
review). The distribution of deprivation scores is also
reported. This was calculated at the point of data extrac-
tion, from patient postcode, using the index of multiple
deprivation (IMD).47 Higher values for IMD score repre-
sent a greater level of socioeconomic deprivation.
The key baseline clinical characteristics of the cohort
were also deﬁned (using an ontological approach where
appropriate) and are also reported; smoking status,
alcohol use, BMI, HbA1c, blood pressure, cholesterol
and renal function (estimated glomerular ﬁltration
rate). Smoking status and alcohol use are reported using
the most recently recorded values. Similarly, BMI,
HbA1c, blood pressure and cholesterol measurements
are reported using the most recently recorded value.
Where data on BMI were missing, we have calculated
BMI from the most recent weight and height measure-
ments. We report the number of people with missing
data for all variables.
Figure 2 Seven-step algorithm for categorising type of diabetes. The number of people classified at by each step is shown.
1Excluding prescriptions for metformin. BMI, body mass index; OHA, oral hypoglycaemic agent.
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Duration of diabetes at the start of follow-up is also
reported. This has been deﬁned as the time since the
ﬁrst diabetes deﬁning event. These events comprise:
ﬁrst diabetes diagnostic code, ﬁrst investigation result
consistent with diabetes or date of ﬁrst prescription of
glucose-lowering medication. We use the duration of
diabetes to identify a recent onset population (those
with a diagnosis of T2DM for <2 years) and report
the characteristics of this subset separately. This subset
of newly diagnosed people with T2DM will enable
a prospective analysis of current trends in early
management.
Clinical codes were also used to deﬁne the presence
of comorbidities and diabetes complications; hyperten-
sion, atrial ﬁbrillation, angina, myocardial infarction,
congestive heart failure, stroke, transient ischaemic
attack, chronic kidney disease (stages 3–5), current renal
replacement therapy, dementia, depression, previous
amputation, peripheral neuropathy, retinopathy (all
stages), peripheral vascular disease, rheumatoid arthritis,
chronic liver disease (all causes) and non-alcoholic fatty
liver disease (NAFLD).
Cohort characteristics
A total of 1 260 761 people were included from 130
primary care practices. In total, 1 015 867 were aged 18
or older on 31 August 2015. From these, 63 465 (6.25%)
people were identiﬁed as having any type of diabetes.
The majority of these (58 717; 91.8%) were categorised
as most likely to have T2DM, and a minority T1DM
Table 1 The characteristics of the complete adult population, adults with T1DM (for comparison) and adults with T2DM
Characteristic
All adults n (%*) or mean
(SD) (N=1 015 867)
Adults with T1DM n (%*)
or mean (SD) (N=4478)
Adults with T2DM n (%*)
or mean (SD) (N=58 717)
Age (years) 47.8 (18.9) 42.3 (15.5) 66.2 (14.1)
Female 518 456 (51.0) 2075 (46.3) 26 706 (45.4)
Ethnicity recorded 733 024 (72.2) 3542 (79.1) 48 199 (82.1)
White 637 288 (62.7) 3208 (71.6) 40 380 (68.8)
Asian 54 632 (5.4) 186 (4.1) 5127 (8.7)
Black 22 705 (2.2) 85 (1.9) 1858 (3.2)
Mixed 9278 (0.9) 40 (0.9) 483 (0.8)
Other 9121 (0.9) 23 (0.5) 351 (0.6)
IMD recorded 959 767 (94.5) 4217 (94.2) 56 522 (96.3)
IMD score† 18.9 (15.4) 19.8 (16.0) 20.5 (16.3)
Smoking status recorded 785 051 (93.0) 3590 (99.4) 50 890 (99.3)
Never 462 574 (54.8) 1995 (55.2) 20 587 (40.2)
Current 322 477 (38.2) 865 (23.9) 7485 (14.6)
Ex-smoker 171 570 (20.3) 1595 (44.1) 30 303 (59.1)
Alcohol use recorded 689 913 (67.9) 3938 (87.9) 54 808 (93.3)
None 163 476 (16.1) 1018 (22.7) 19 499 (33.2)
Within limits 297 526 (29.3) 1373 (30.7) 14 176 (24.1)
Excess 228 911 (22.5) 1547 (34.5) 21 133 (36.0)
Duration of diabetes recorded − 4478 (100.0) 58 717 (100.0)
<4 years − 943 (21.1) 18 513 (31.5)
4≤x<7 years − 654 (14.6) 11 516 (19.6)
7≤x<10 years − 760 (17.0) 11 321 (19.3)
≥10 years − 2121 (47.4) 17 092 (29.1)
HbA1c measured − 4288 (95.8) 57 501 (97.9)
HbA1c (mmol/mol) − 69.8 (20.9) 56.1 (16.5)
BMI measured 803 995 (79.1) 4377 (97.7) 57 557 (98.0)
BMI (kg/m2) 26.6 (5.9) 26.2 (6.2) 31.4 (6.6)
Blood pressure measured 847 028 (83.4) 4478 (99.0) 58 379 (99.4)
SBP (mm Hg) 126.6 (15.4) 126.1 (14.5) 131.4 (14.4)
DBP (mm Hg) 76.0 (9.7) 74.1 (9.2) 75.0 (9.4)
Total cholesterol measured 77 120 (7.6) 723 (16.1) 8025 (13.7)
Total cholesterol (mmol/L) 5.3 (1.1) 4.6 (1.1) 4.9 (1.3)
LDL cholesterol measured 424 756 (41.8) 3482 (77.8) 51 336 (87.4)
LDL cholesterol (mmol/L) 3.2 (1.0) 2.6 (0.9) 3.0 (1.1)
eGFR recorded 586 052 (57.7) 4054 (90.5) 57 404 (97.8)
*Percentage values shown are of the column total.
†A higher score equates to a higher level of deprivation although the scale is non-linear.
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; IMD, index
of multiple deprivation; LDL, low-density lipoprotein; SBP, systolic blood pressure; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes
mellitus.
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(4478; 7.62%) or not categorised (270; 0.43%) (ﬁgure 2).
The crude prevalence of T2DM in the adult population
was 5.78% and direct standardised prevalence (using the
2011 UK census44) similar at 5.78% (95% CI 5.72% to
5.82%).
The mean age of the T2DM cohort was 66.2 (SD 14.1)
years and 26 706 (45.4%) were female (table 1). The age
and gender distribution is shown in ﬁgure 3. The crude
prevalence of cardiovascular comorbidities was higher in
adults with T2DM than T1DM; however, the age and
gender standardised rates were similar (tables 2 and 3,
respectively). A higher prevalence of diabetes complications
(peripheral vascular disease, peripheral neuropathy, retin-
opathy and chronic kidney disease) were seen in people
with T1DM after age and gender standardisation (table 3).
The crude prevalence of T2DM varied considerably by
ethnicity: white 6.34%, Asian 9.38%, black 8.18%, mixed
5.21%, other 3.85% and no ethnicity identiﬁed 3.72%.
After adjusting for age and gender, the prevalence of
T2DM remained highly variable across ethnicity groups:
white 5.91% (95% CI 5.85% to 5.96%), Asian 16.99%
(16.48% to 17.52%), black 13.84% (13.11% to 14.65%),
mixed 11.81% (10.62% to 13.46%), other 9.25% (8.10%
to 10.65%) and no ethnicity identiﬁed 3.74% (3.67% to
3.81%). Clinical characteristics also vary considerably by
ethnicity in people with T2DM (table 4).
Metformin was the most commonly prescribed dia-
betes medication in people with T2DM (table 5). In
total, 12 284 (20.9%) people had no diabetes medica-
tion prescribed. The subset of people with recent onset
(<2 years) had a lower prevalence of complications than
the complete cohort of people with T2DM (table 6).
DISCUSSION AND FINDINGS TO DATE
A large cohort (N=58 717) of adults with T2DM has
been identiﬁed from the RCGP RSC population. The
characteristics of this cohort are described here and
compared with those of the complete adult population
and a population of people with T1DM. We have identi-
ﬁed a large burden of macrovascular and microvascular
disease in our T2DM cohort and a broad range of ther-
apies in use. This baseline analysis demonstrates high
levels of data completeness in the diabetes population
for a range of variables including ethnicity, smoking
status, alcohol use, HbA1c, BMI, blood pressure, low-
density lipoprotein cholesterol and renal function. This
is higher than that reported for other T2DM
Figure 3 The age and gender profile of the cohort of people with T2DM. T2DM, type 2 diabetes mellitus.
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populations identiﬁed from other large UK-based popu-
lation databases; such as the QResearch database and
the Clinical Practice Research Database (CPRD).45
Given that this T2DM cohort has a high level of data
completeness, a long duration of follow-up, a range of
socioeconomic and ethnic groups represented, and
covers people with a range of diabetes medications and
with a range of diabetes-related complications, it is ideally
suited for a number of different population-based studies.
The planned analyses include medication adherence and
persistence, thresholds for changing therapies (in particu-
lar treatment intensiﬁcation), and socioeconomic and
ethnic disparities in management and outcomes.
The crude prevalence of most comorbidities was
higher in people with T2DM than those with T1DM.
Similar trends have been reported in a large UK-based
population.48 However, most diabetes complications
(peripheral neuropathy, retinopathy and amputations)
were more prevalent in people with T1DM. In contrast,
age-adjusted and gender-adjusted rates of comorbidities
were similar between the groups. After adjustment, only
hypertension remained more prevalent in T2DM,
whereas the prevalence of peripheral neuropathy, retin-
opathy and peripheral vascular disease remained higher
in people with T1DM.
Ethnic differences in diabetes prevalence are well
established.49 Our data show that the T2DM prevalence
has increased in all ethnicity groups when compared
with UK data reported 10 years ago.50 In addition, our
data demonstrate substantial variation in clinical
characteristics across these groups.
Strengths and limitations
We have recently reported that the RCGP RSC popula-
tion is broadly representative of the national population
albeit with some oversampling of 25–44 years old, and
less deprived people.51 In addition to the strengths
already discussed, this subcohort of people with T2DM
has the advantages of large size and of a high frequency
of data uploads which enable prospective follow-up.
Data are uploaded to the RCGP RSC database weekly.
An additional strength of the cohort is of high-quality
recording of infectious diseases (primary care practices
which comprise the RCGP RSC receive regular feedback
on the quality of their recording of infectious diseases,
which should ensure a high standard of recording). This
has already enabled analysis of infection rates in elderly
people with T2DM.52 Furthermore, many of the UK
primary care pay-for-performance targets for people
with T2DM include recording and monitoring of disease
indicators relevant to diabetes such as HbA1c, periph-
eral neuropathy and renal function, which have led to
the high level of data completeness reported here.
Limitations include the observational nature of the
data and some residual incompleteness of recording of
variables. Incomplete data recording in people with dia-
betes is disproportionately more common in people with
poor outcomes.53 The network is also comprised of vol-
unteer practices, which may be better at managing dia-
betes and related conditions or at recording these
conditions than other primary care practices. Indeed we
have previously reported that the included practices
score more highly on pay-for-performance targets.51
Table 2 The number of people with common comorbidities of the complete adult population, adults with T1DM
(for comparison), and adults with T2DM
Comorbidities
All adults n (%)
(N=1 015 867)
Adults with T1DM n
(%) (N=4478)
Adults with T2DM n (%)
(N=58 717)
Hypertension 164 502 (16.2) 967 (21.6) 33 467 (57.0)
Atrial fibrillation 25 209 (2.5) 53 (1.2) 5253 (8.9)
Angina 17 837 (1.8) 83 (1.9) 4688 (8.0)
Myocardial infarction 11 227 (1.1) 73 (1.6) 2697 (4.6)
Congestive heart failure 11 216 (1.1) 61 (1.4) 3146 (5.4)
Stroke 12 120 (1.2) 50 (1.1) 2366 (4.0)
Transient ischaemic attack 9870 (1.0) 28 (0.6) 1838 (3.1)
Chronic kidney disease 41 054 (4.0) 285 (6.4) 10 585 (18.0)
Renal replacement therapy 1163 (0.1) 56 (1.3) 312 (0.5)
Dementia 9964 (1.0) 19 (0.4) 1883 (3.2)
Depression 95 941 (9.4) 657 (14.7) 6927 (10.7)
Amputation 1799 (0.2) 65 (1.5) 472 (0.8)
Peripheral neuropathy 7170 (0.7) 326 (7.3) 3847 (6.6)
Retinopathy 24 698 (2.4) 2667 (59.6) 21 396 (36.4)
Peripheral vascular disease 6820 (0.7) 98 (2.2) 2172 (3.7)
Rheumatoid arthritis 8519 (0.8) 40 (0.9) 1028 (1.8)
Chronic liver disease* 10 651 (1.0) 80 (1.8) 2638 (4.5)
NAFLD 6530 (0.6) 54 (1.2) 1989 (3.4)
*All liver disease including NAFLD.
NAFLD, non-alcoholic fatty liver disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
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Table 3 Crude and age-standardised and gender-standardised prevalence (compared with the 2011 population census) for common comorbidities of the complete adult
population, adults with T1DM (for comparison), and adults with T2DM
All adults (N=1 015 867) Adults with T1DM (N=4478) Adults with T2DM (N=58 717)
Comorbidities
Crude
prevalence (%)
Adjusted prevalence
(95% CI) (%)
Crude
prevalence (%)
Adjusted prevalence
(95% CI) (%)
Crude
prevalence (%)
Adjusted prevalence
(95% CI) (%)
Hypertension 16.2 16.1 (16.1 to 16.2) 21.6 28.1 (25.9 to 30.9) 57.0 34.6 (33.9 to 35.9)
Atrial fibrillation 2.48 2.42 (2.39 to 2.46) 1.18 2.00 (1.44 to 3.38) 8.94 3.47 (3.34 to 4.50)
Angina 1.76 1.73 (1.70 to 1.75) 1.85 2.70 (2.09 to 4.11) 7.98 3.49 (3.31 to 4.53)
Myocardial infarction 1.11 1.09 (1.07 to 1.11) 1.63 2.32 (1.74 to 3.70) 4.59 2.23 (2.08 to 3.36)
Congestive heart
failure
1.11 1.08 (1.06 to 1.10) 1.36 2.62 (1.75 to 4.29) 5.36 2.37 (2.19 to 3.43)
Stroke 1.19 1.17 (1.15 to 1.19) 1.11 1.85 (1.33 to 3.21) 4.03 1.73 (1.65 to 2.78)
Transient ischaemic
attack
0.97 0.95 (0.93 to 0.97) 0.63 1.01 (0.65 to 2.31) 3.13 1.31 (1.24 to 2.37)
Chronic kidney
disease
4.23 4.15 (4.11 to 4.19) 6.47 10.8 (9.26 to 12.9) 18.7 7.67 (7.42 to 8.72)
Renal replacement
therapy
0.11 0.11 (0.11 to 0.12) 1.25 1.21 (0.90 to 2.45) 0.53 0.33 (0.28 to 1.47)
Dementia 0.98 0.94 (0.92 to 0.96) 0.42 1.19 (0.68 to 2.61) 3.21 1.13 (1.07 to 2.19)
Depression 9.44 9.50 (9.44 to 9.56) 14.7 14.4 (13.2 to 16.2) 11.8 14.7 (13.9 to 16.1)
Amputation 0.17 0.17 (0.17 to 0.18) 1.45 1.80 (1.33 to 3.12) 0.80 0.41 (0.36 to 1.53)
Peripheral
neuropathy
0.71 0.70 (0.68 to 0.71) 7.28 9.38 (8.12 to 11.3) 6.55 3.44 (3.30 to 4.48)
Retinopathy 2.43 2.42 (2.39 to 2.46) 59.6 62.8 (60.1–66.0) 36.4 23.6 (22.9 to 24.9)
Peripheral vascular
disease
0.67 0.66 (0.64 to 0.68) 2.18 3.42 (2.70 to 4.89) 3.70 1.53 (1.46 to 2.59)
Rheumatoid arthritis 0.84 0.84 (0.83 to 0.86) 0.89 1.32 (0.89 to 2.65) 1.75 1.08 (0.99 to 2.15)
Chronic liver
disease*
1.05 1.06 (1.03 to 1.07) 1.78 1.66 (1.29 to 2.91) 4.49 4.70 (4.25 to 5.86)
NAFLD 0.64 0.64 (0.63 to 0.66) 1.21 1.07 (0.79 to 2.31) 3.39 3.80 (3.37 to 4.97)
*All liver disease including NAFLD.
NAFLD, non-alcoholic fatty liver disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
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Finally, while in our experience, the proportion of
people with T2DM moving practices is generally small,
anyone who moves to a practice which is not part of the
RCGP RSC network will be lost to follow-up.
Collaboration
We encourage collaboration with researchers interested
in pursuing research questions regarding the
identiﬁcation, management, natural history or trends in
people with diabetes which can be addressed using this
large observational data set either prospectively or retro-
spectively. The database can be made available to
researchers on a case-by-case basis and is subject to
ethical approval for each study by the National Health
Service (NHS) Research Ethics Committee. The policy
of the RCGP is that patient-level data must remain
Table 4 Clinical characteristics of people with T2DM (N=58 717) by ethnicity group
Characteristic
White n (%) or
mean (SD)
(N=40 380)
Asian n (%)
or mean (SD)
(N=5127)
Black n (%) or
mean (SD)
(N=1858)
Mixed n (%) or
mean (SD)
(N=483)
Other n (%) or
mean (SD)
(N=351)
Not recorded n
(%) or mean
(SD) (N=12 128)
Age (years) 67.5 (13.6) 58.4 (14.4) 59.6 (13.7) 60.2 (14.3) 57.5 (13.4) 66.6 (14.3)
IMD recorded 38 949 (96.5) 4888 (95.3) 1780 (95.8) 463 (95.9) 338 (96.3) 10 104 (96.1)
IMD score* 19.4 (16.0) 27.6 (17.6) 30.8 (14.5) 24.8 (16.3) 25.9 (15.5) 19.4 (15.8)
Smoking status
recorded
40 380 (99.8) 5127 (99.7) 1858 (99.9) 483 (99.6) 351 (99.7) 10 518 (97.6)
Never 12 320 (30.5) 2812 (54.8) 1047 (56.4) 236 (48.9) 157 (44.7) 4015 (38.2)
Current 5413 (13.4) 564 (11.0) 167 (9.0) 63 (13.0) 53 (15.1) 1225 (11.6)
Ex-smoker 22 574 (55.9) 1737 (33.9) 642 (34.6) 182 (37.7) 140 (39.9) 5028 (47.8)
Alcohol use
recorded
38 640 (95.7) 4950 (96.5) 1787 (96.2) 466 (96.5) 333 (94.9) 8632 (82.1)
None 11 295 (28.0) 3435 (67.0) 1027 (55.3) 218 (45.1) 193 (55.0) 3331 (31.7)
Within limits 10 284 (25.5) 726 (14.2) 428 (23.0) 118 (24.4) 68 (19.4) 2552 (24.3)
Excess 17 061 (42.3) 789 (15.4) 332 (17.9) 130 (26.9) 72 (20.5) 2749 (26.1)
Duration of diabetes
<4 years 11 856 (29.4) 1936 (37.8) 708 (38.1) 193 (40.0) 140 (39.9) 3680 (35.0)
4≤x<7 years 8039 (19.9) 988 (19.3) 393 (21.2) 97 (20.1) 80 (22.8) 1919 (18.2)
7≤x<10 years 8107 (20.1) 905 (17.7) 295 (15.9) 84 (17.4) 67 (19.1) 1863 (17.7)
≥10 years 12 378 (30.7) 1298 (25.3) 462 (24.9) 109 (22.6) 64 (18.2) 3056 (29.1)
HbA1c
measured
39 687 (98.3) 5054 (98.6) 1819 (97.9) 472 (97.7) 342 (97.4) 10 127 (96.3)
HbA1c
(mmol/mol)
55.9 (16.3) 57.3 (16.8) 58.7 (20.6) 56.4 (17.5) 57.0 (19.0) 56.0 (16.4)
BMI measured 39 898 (98.8) 5062 (98.7) 1819 (97.9) 480 (99.4) 344 (98.0) 9954 (94.6)
BMI (kg/m2) 31.9 (6.6) 28.4 (5.3) 31.3 (6.5) 30.4 (6.1) 29.8 (5.6) 31.5 (6.6)
Blood pressure
measured
40 271 (99.7) 5104 (99.6) 1844 (99.2) 483 (100.0) 351 (100.0) 10 326 (98.2)
SBP (mmHg) 128.2 (19.6) 120.0 (22.6) 123.5 (24.6) 126.2 (18.5) 121.0 (23.3) 118.0 (28.5)
DBP (mmHg) 78.0 (17.1) 82.0 (21.1) 86.6 (23.6) 78.3 (16.5) 83.4 (21.8) 89.2 (26.7)
*A higher score equates to a higher level of deprivation although the scale is non-linear.
BMI, body mass index; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; IMD, index of multiple deprivation; SBP, systolic blood
pressure; T2DM, type 2 diabetes mellitus.
Table 5 Proportion of people with T2DM (n=58 717) prescribed medications in the past 1, 3 and 10 years prior to 31 July 2015
Medication
Prescribed in past
1 year n (%)
Prescribed in past
3 years n (%)
Prescribed in past
10 years n (%)
Metformin 37 045 (63.1) 39 872 (67.9) 43 179 (73.5)
Thiazolidinediones 1826 (3.1) 2642 (4.5) 5989 (10.2)
Sulfonylureas 15 547 (26.5) 17 696 (30.1) 20 819 (35.5)
Meglitinides 174 (0.3) 257 (0.4) 541 (0.9)
DPP-4 inhibitors 6941 (11.8) 8462 (14.4) 9453 (16.1)
α-glucosidase inhibitors 98 (0.2) 146 (0.2) 295 (0.5)
SGLT2 inhibitors 1267 (2.2) 1267 (2.2) 1267 (2.2)
GLP1 analogues 1930 (3.3) 2497 (4.3) 2842 (4.8)
Insulin 8403 (14.3) 8806 (15.0) 9442 (16.1)
DPP-4, dipeptidase IV; GLP1, glucagon-like peptide 1; SGLT2, sodium glucose co-transporter 2; T2DM, type 2 diabetes mellitus.
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within the secure network at the University of Surrey.
Direct access for interested researchers can be arranged
subject to the information governance standards of the
University of Surrey, alternatively aggregated data can be
provided. We encourage interested researchers to attend
the short courses on how to analyse primary care data
offered by the university biannually.
CONCLUSION
We have devised methods to optimise the identiﬁcation
of diabetes and diabetes subtype from the routine data
collected. The large population of people with T2DM
identiﬁed from the RCGP RSC cohort provides an excel-
lent opportunity to use real-world evidence to explore
the clinical use and impact of newer diabetes therapies
in clinical practice, and observation of the clinical man-
agement of T2DM in practice. We encourage collabora-
tive use of this data set with interested researchers.
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